Protagonist Therapeutics, Inc.
PTGX
주식 순위
#2221
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to... Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
주가
$138.22
마지막 동기화: 2026-10-21
시가총액
$8.94B
변동 (1일)
0.16%
변동 (1년)
88.05%
국가
US
거래 Protagonist Therapeutics, Inc. (PTGX)
카테고리
Healthcare
Protagonist Therapeutics, Inc. (PTGX)의 주가 이력
최고 종가: $138.58 (2026-10-01 기준)
최저 종가: $11.34 (2016-08-01 기준)
최저 종가: $11.34 (2016-08-01 기준)
Protagonist Therapeutics, Inc.의 주가 이력 (2016 ~ 2026)
연간 주가 성과
| 연도 | 성과 |
|---|---|
| 2026 (TTM) | 21.74% |
| 2025 | 119.26% |
| 2024 | 92.93% |
| 2023 | 131.51% |
| 2022 | -72.05% |
| 2021 | 46.48% |
| 2020 | 203.82% |
| 2019 | 9.00% |
| 2018 | -65.01% |
| 2017 | -15.57% |
| 2016 | 0.00% |
유사 기업 또는 경쟁사의 주가
| 회사 | 주가 | 변동률 1년% | 국가 |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $766.95 | 9.01% |
CH
|
